OBJECTIVE: Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) affect degradation of vascular elastin, collagen remodelling and formation of atherosclerotic plaque. This crosssectional study investigated the levels of MMP-9 and TIMP-1 mRNAs in the blood of patients with primary hypertension with and without hypertension-induced carotid atherosclerosis. METHODS: Hypertensive patients with and without atherosclerosis and age-and gender-matched normotensive subjects were enrolled. MMP-9 and TIMP-1 mRNA were quantified using real-time reverse transcription-polymerase chain reaction. RESULTS: Hypertensive patients (n = 86) had significantly lower levels of TIMP-1 mRNA than normotensive subjects (n = 43).
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Hypertensive patients with atherosclerosis (n = 42) showed significantly elevated levels of MMP-9 mRNA compared with both normotensive subjects and hypertensive patients without atherosclerosis (n = 44). CONCLUSIONS: Primary hypertension resulted in decreased TIMP-1 mRNA levels, suggesting a potential mechanism contributing to the degradation of elastin. Hypertension-induced atherosclerosis was associated with significantly increased levels of MMP-9 mRNA, which may Introduction Alterations in the mechanical properties and structural composition of large arteries and resistance vessels contribute to cardiovascular complications including hypertension and organ impairment. 1, 2 Arterial hypertension is associated with vascular remodelling, arterial atherosclerosis and left ventricular (LV) hypertrophy. Arterial atherosclerosis develops from the W Su, F Gao, J Lu et al. MMP-9 and TIMP-1 mRNAs in hypertension-induced atherosclerosis abnormal migration and proliferation of vascular smooth muscle and endothelial cells, as well as the regional deposition of secreted extracellular matrix (ECM). 3 This disease process contributes to impaired arterial relaxation and altered cardiac function, as well as the development of hypertension and organ impairment.
The ECM is responsible for the threedimensional spatial arrangement and structural integrity of the arterial wall and the metabolic function of intracellular components. 4 -7 Alterations have been reported in the density, architecture and composition of the ECM in vessels and myocardium as a result of hypertension. 5 -7 Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) play a vital role in the regulation of ECM metabolism in both normal and pathological conditions. 8 MMP-9 digests gelatin, elastin, fibronectin, laminin, and types IV and V collagen, which are found in subendothelial basement membranes. 9,10 TIMP-1 blocks the activation of MMPs, preventing their proteolytic activity. 9, 10 MMPs and TIMPs regulate the metabolism of collagen and elastin and are, therefore, responsible for structural and functional alterations in the arterial wall during hypertension.
Synthesis of MMP-9 occurs in atherosclerotic plaques. 11 Levels of MMP-9 have been reported to be significantly higher in the coronary artery than in the systemic circulation after acute myocardial infarction. 12, 13 In addition, evidence suggests that plaque rupture may release MMP-9 into coronary arteries. 13, 14 Increased MMP-9 levels are suggestive of atherosclerotic wall remodelling and plaque destabilization.
Elevated TIMP-1 levels have been found in hypertensive patients. 15 -17 An increase in TIMP-1 decreases the levels of activated MMP-1, thereby preventing the breakdown of type I collagen and contributing to myocardial fibrosis-altered diastolic function. 17 TIMP-1 may, therefore, be considered a biomarker of tissue fibrosis.
Findings regarding plasma MMP-9 and TIMP-1 levels in hypertensive patients have been inconsistent, with studies variously reporting increases or decreases. 15,18 -21 It is thought that plasma MMP-9 mRNA levels may be closely linked to the development of arterial atherosclerosis, and a correlation may exist between TIMP-1 mRNA levels and vascular remodelling and fibrosis. The current study, therefore, investigated the levels of MMP-9 and TIMP-1 mRNAs in the peripheral blood of hypertensive patients, hypertensive patients with atherosclerosis, and normotensive control subjects.
Patients and methods

STUDY POPULATION
Consecutive patients with essential hypertension (blood pressure > 140/90 mmHg; intima-media thickness [IMT] > 1.2 mm) were recruited to this cross-sectional observational study at the Department of Cardiology, Wuxi Hospital Affiliated with Nanjing University of Chinese Medicine, Wuxi City, China, between June 2009 and February 2010. Exclusion criteria were: (i) smoking; (ii) conditions associated with alterations in serum levels of MMP-9 or TIMP-1 (rheumatoid arthritis, cancer, systemic inflammatory disease, acute myocardial infarction, LV hypertrophy, infectious disease, pulmonary fibrosis, hyperlipidaemia and hepatic fibrosis); (iii) renal or hepatic insufficiency; (iv) chronic obstructive pulmonary disease; (v) stroke, arrhythmia or chronic heart failure; and (vi) diabetes mellitus. Patients who were receiving pharmacological treatment for W Su, F Gao, J Lu et al.
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their hypertension were required to discontinue drug therapy for > 1 week before the onset of the study.
Healthy age-and sex-matched volunteers who had normal blood pressure (≤ 140/90 mmHg) and were not receiving any drug treatment were recruited from those attending Wuxi Hospital Affiliated with Nanjing University of Chinese Medicine for routine health examination.
The study protocol was approved by the Ethics Committee on Human Research, Wuxi Hospital Affiliated with Nanjing University of Chinese Medicine. All study participants provided verbal informed consent prior to enrolment.
BLOOD PRESSURE MEASUREMENT
Blood pressure was determined in all study participants using a mercury-type sphygmomanometer cuff after a minimum resting period of 15 min and with the subject seated. The median of three measurements was recorded.
CAROTID ULTRASONOGRAPHY
Carotid ultrasonography was performed on all study participants with a high-resolution linear array transducer (probe frequency 7.5 MHz) and a Doppler ultrasonography system (LOGIQ ® 7; GE Medical Systems, Milwaukee, WI, USA). Images were obtained at the distal carotid artery, the carotid artery bulb and the proximal 2 cm of the internal carotid artery (two images at each location). IMT was measured at each location in both carotid arteries with all images gated to diastole, and the mean of the maximal IMT measurements for the right and left carotid arteries was recorded. The LV septum thickness, LV posterior wall thickness and LV end-diastolic diameter were determined using the Doppler ultrasonography system (LOGIQ ® 7) and a phased array transducer (probe frequency 2 -4 MHz). Patients with hypertension were divided into two groups (with or without carotid atherosclerotic plaques) based on the results of the ultrasonographic examination.
BLOOD SAMPLING AND LABORATORY ANALYSES
Blood (5 ml) was obtained from all subjects in the morning after an overnight fast (typically between 7.30 h and 9.00 h). Blood was collected in tubes containing 1.8 mg/ml sodium ethylenediaminetetra-acetic acid and analysed for glucose, blood urea nitrogen, creatinine, low-density lipoprotein and high-density lipoprotein using a biochemical analyser (Model P800 [SN: 1832-09]; Roche Diagnostics GmbH, Mannheim, Germany). An aliquot of each blood sample was frozen at -70°C for analysis of MMP-9 and TIMP-1 mRNA levels. The primer sequences were: MMP-9, forward 5′-TCTTCCCTGGAGACCTGAGA-3′ and reverse 5′-ATTTCGACTCTCTCCACGCAT C-3′; TIMP-1, forward 5′-TGACATCCGGTTC GTCTACA-3′ and reverse 5′-TGCAGTTTTC CAGCAATGAG-3′; and glyceraldehyde 3phosphate dehydrogenase (GAPDH), forward 5′-ACAGTCAGCCGCATCTTCTT-3′ and reverse 5′-ACGACCAAATCCGTTGACT C-3′. The cycling programme involved preliminary denaturation at 95°C for 30 s, followed by 40 cycles of denaturation at 95°C for 5 s, annealing at 60°C for 20 s, and extension at 60°C for 20 s, followed by a final extension step at 70°C for 5 min. Quantification of the relative mRNA levels for MMP-9 and TIMP-1 was carried out using GAPDH as an internal reference, according to the following formula: C T (target gene) -C T (reference gene) = ∆C T . The relative mRNA levels of each gene were then calculated using the 2 -∆∆CT method: ∆C T (sample) -∆C T (calibrator) = ∆∆C T . The fold-changes of mRNA levels were reported as relative expression.
REAL-TIME QUANTITATIVE RT-PCR
Specificity of the PCR was confirmed by sequencing analysis using a 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA) and Chromas Software, version 2.01 (Technelysium, Brisbane, Australia). Sequences were compared with file sequences from GenBank (available at: http://www.ncbi.nlm.nih.gov/genbank/).
STATISTICAL ANALYSES
Data were reported as mean ± SD. Statistical analyses were performed using the SPSS ® statistical package, version 11.5 (SPSS Inc., Chicago, IL, USA) for Windows ® . Continuous variables were compared using analysis of variance, and categorical variables were compared using the χ 2 -test. Any two mean values were compared with the Fisher's least significant difference test. A P-value < 0.05 was considered to be statistically significant.
Results
The study population comprised 86 patients with essential hypertension and 43 normotensive age-and sex-matched control subjects. The hypertensive population included 42 patients with and 44 patients without carotid atherosclerotic plaques. Of the patients with hypertension, 35 had been receiving no pharmacological intervention and the remaining 51 patients had discontinued drug therapy > 1 week before the onset of the study. The demographic and clinical characteristics of the study participants are shown in Table 1 . Patients with hypertension (with or without atherosclerosis) had significantly higher systolic and diastolic blood pressure and pulse pressure than normotensive controls (P < 0.05 for all comparisons). There were no significant differences in any other demographic or clinical parameters.
Representative ultrasonography images of the left and right common carotid arteries of a patient with carotid atherosclerosis are shown in Figs 1A and 1B , respectively. Atherosclerotic plaques were present in both sides of the common carotid artery (arrows). These plaques induced severe luminal stenosis (Fig. 1C; arrow) producing an increase in turbulent blood flow ( Fig. 1D ; blue region).
The sequences of the MMP-9 and TIMP-1 PCR amplification products correlated well with the known sequences for MMP-9 and TIMP-1 as published in GenBank. The levels of MMP-9 and TIMP-1 mRNAs are shown in Table 2 . Hypertensive patients with W Su, F Gao, J Lu et al.
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atherosclerosis had significantly higher MMP-9 mRNA levels than both normotensive controls and hypertensive patients without atherosclerosis (P < 0.05 for both comparisons). Hypertensive patients without atherosclerosis had a significantly lower level of TIMP-1 mRNA than normotensive controls (P < 0.05).
Discussion
Alterations in the composition and structure of the ECM are important determinants in hypertension-induced vascular remodelling. 22 MMP-9 and TIMP-1 play a vital role in ECM changes during physiological and pathological conditions. 8 The MMP-9 mRNA level was significantly higher in patients with hypertension and atherosclerosis compared with patients with hypertension alone and normotensive controls in the present study. In addition, the TIMP-1 mRNA level was lower in hypertensive patients without atherosclerosis than in normotensive control subjects.
Conflicting results have been reported regarding plasma levels of MMP-9 and TIMP-1 in hypertensive patients, with studies variously showing increases or decreases in plasma MMP-9 and TIMP-1 levels. 15,18 -21 This inconsistency may be due to the lack of experimental control groups in these studies, resulting in patients being compared at various stages of hypertension. 21 In addition, confounding disease states such as systolic hypertension, diastolic myocardial dysfunction and LV hypertrophy were not W Su, F Gao, J Lu et al.
TABLE 1: Demographic and clinical characteristics of normotensive control subjects, patients with hypertension and patients with hypertension and carotid artery atherosclerosis included in the present study to investigate the levels of metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 mRNAs in peripheral blood
Patients with hypertension
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excluded from these studies. 19, 20 By excluding patients with LV hypertrophy prior to patient enrolment, the present study focused on changes in plasma mRNA levels of MMP-9 and TIMP-1 specifically in patients with hypertension and hypertension-induced atherosclerosis. The similarities between the clinical and laboratory data in patients and controls in the present study indicated that other systemic conditions that might affect the levels of MMP-9 and TIMP-1 mRNA, including diabetes, renal insufficiency and hyperlipidaemia, had also been effectively excluded.
Elastin is the primary elastic element of the arterial wall, accounting for approximately 40% by dry weight analysis. 4 Elastin is susceptible to degradation by serine proteases, especially MMP-9. 9,10,23 Increased levels of MMP-9 are associated with 23 Studies have found an increase in inflammatory cytokines, MMP-9, MMP-2 and serum elastase activity in hypertensive patients, possibly contributing to altered vascular reactivity. 23, 24 Electron microscopic analysis of the media layer in hypertensive patients has revealed an increase in the collagen-elastin ratio, which is believed to be largely due to increased degradation of elastin via elevated MMP-9 levels. 25 MMP-9 mRNA levels were increased in patients with hypertension and atherosclerosis compared with both other groups in the present study. Although similar changes in MMP-9 mRNA levels were not observed in hypertensive patients without atherosclerosis, TIMP-1 mRNA levels were decreased in these patients. As TIMP-1 inhibits the enzymatic activity of MMP-9, 8 a decrease in TIMP-1 mRNA may be associated with elevated MMP-9 activity despite constant MMP-9 mRNA levels. The consequent elevated MMP-9 may be partly responsible for primary hypertension. 26 Fibrillar collagen types I and III predominate in the cardiovascular ECM. 7, 8, 22 The former has high tensile strength and rigidity, and the latter provides elasticity. 7, 8, 22 Increased interstitial and perivascular deposition of fibrillar collagen has been found in the vasculature of hypertensive patients and in hypertrophied hearts. 7, 16, 27, 28 These pathological changes are believed to be responsible for the increased vascular stiffness and reduced vascular compliance associated with hypertension. The proteinase MMP-1 degrades structural collagen types I and III and is specifically inhibited by TIMP-1. 17 Increased TIMP-1 and the consequent decrease in MMP-1 activity resulted in a reduction in the turnover of extracellular collagen types I and III and increased vascular fibrosis in patients with hypertension. 17 Collagen types IV and V are the major substrates of MMP-9, and elevated MMP-9 levels have been shown to result in breakdown of these collagen types, leading to a net increase in the proportion of types I and III collagen in hypertension. 20 The elevation of MMP-9 mRNA levels in patients with hypertension and atherosclerosis in the present study may have led to a net increase in collagen types I and III in the vascular wall via the degradation of collagen types IV and V. These findings are consistent with a postulated mechanism for the reduction in • Received for publication 9 January 2012 • Accepted subject to revision 17 January 2012 • Revised accepted 4 April 2012 Copyright © 2012 Field House Publishing LLP fibrillar collagen turnover that has been observed in midstage isolated hypertension. 17 Atherosclerotic plaques have been found to contain increased levels of immunoactive TIMP-1 compared with normal arterial tissue. 29 In addition, the region of cell accumulation in atherosclerotic plaques has been shown to have increased levels of immunoactive MMP-9. 13, 14 Cellular components of the plaque, which include macrophages, smooth muscle cells and endothelial cells, are known to produce several proteinases. 13, 14 When plaque rupture causes acute myocardial infarction, plasma levels of MMP-9 are elevated in the coronary artery relative to the systemic circulation. 13 Elevated levels of MMP-9 and TIMP-1 might, therefore, be partly attributable to secretion from atherosclerotic plaques.
In conclusion, primary hypertension was associated with decreased levels of TIMP-1 mRNA in the present study. This could result in increased MMP-9 enzymatic activity and the consequent degradation of arterial elastin, which is responsible for the preliminary stage of hypertension. The significantly elevated MMP-9 mRNA levels observed in hypertensive patients with atherosclerosis may enhance both the deposition of types I and III collagen and atherosclerotic plaque formation.
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